Chinese Journal of Ophthalmology and Otorhinolaryngology, Volume. 25, Issue 4, 292(2025)
Research status on medical quality control for diabetic retinopathy screening and clinical classification
[1] [1] SUN H, SAEEDI P, KARURANGA S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Res Clin Pract, 2022, 183: 109119. DOI: 10.1016/j.diabres.2021.109119.
[3] [3] ZHOU J, CHEN B. Retinal cell damage in diabetic retinopathy[J]. Cells, 2023, 12(9): 1342. DOI: 10.3390/cells12091342.
[4] [4] HOU X H, WANG L M, ZHU D L, et al. Prevalence of diabetic retinopathy and vision-threatening diabetic retinopathy in adults with diabetes in China[J]. Nat Commun, 2023, 14(1): 4296. DOI: 10.1038/s41467-023-39864-w.
[5] [5] TING D S W, CHEUNG G C M, WONG T Y. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review[J]. Clin Exp Ophthalmol, 2016, 44(4): 260-277. DOI: 10.1111/ceo.12696.
[10] [10] PANDIT R J, TAYLOR R. Quality assurance in screening for sight-threatening diabetic retinopathy[J]. Diabet Med, 2002, 19(4): 285-291. DOI: 10.1046/j.1464-5491.2002.00722.x.
[11] [11] GARVICAN L, SCANLON P H. A pilot quality assurance scheme for diabetic retinopathy risk reduction programmes[J]. Diabet Med, 2004, 21(10): 1066-1074. DOI: 10.1111/j.1464-5491.2004.01300.x.
[12] [12] TEO Z L, THAM Y C, YU M, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045 systematic review and meta-analysis[J]. Ophthalmology, 2021, 128(11): 1580-1591. DOI: 10.1016/j.ophtha.2021.04.027.
[13] [13] LIM J I, KIM S J, BAILEY S T, et al. Diabetic Retinopathy Preferred Practice Pattern®[J]. Ophthalmology, 2025, 132(4): 75-162. DOI: 10.1016/j.ophtha.2024.12.020.
[14] [14] SCANLON P H. The English national screening programme for diabetic retinopathy 2003–2016[J]. Acta Diabetol, 2017, 54(6): 515-525. DOI: 10.1007/s00592-017-0974-1.
[15] [15] AVIDOR D, LOEWENSTEIN A, WAISBOURD M, et al. Cost-effectiveness of diabetic retinopathy screening programs using telemedicine: a systematic review[J]. Cost Eff Resour Alloc, 2020, 18: 16. DOI: 10.1186/s12962-020-00211-1.
[17] [17] WONG T Y, SUN J, KAWASAKI R, et al. Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings[J]. Ophthalmology, 2018, 125(10): 1608-1622. DOI: 10.1016/j.ophtha.2018.04.007.
[18] [18] TAN G S, CHEUNG N, SIM R, et al. Diabetic macular oedema[J]. Lancet Diabetes Endocrinol, 2017, 5(2): 143-155. DOI: 10.1016/S2213-8587(16)30052-3.
[19] [19] SOLOMON S D, CHEW E, DUH E J, et al. Diabetic retinopathy: a position statement by the American diabetes association[J]. Diabetes Care, 2017, 40(3): 412-418. DOI: 10.2337/dc16-2641.
[20] [20] AMOAKU W M, GHANCHI F, BAILEY C, et al. Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group[J]. Eye (Lond), 2020, 34(Suppl 1): 1-51. DOI: 10.1038/s41433-020-0961-6.
[22] [22] MOINUL P, BARBOSA J, QIAN J, et al. Does patient education improve compliance to routine diabetic retinopathy screening?[J]. J Telemed Telecare, 2020, 26(3): 161-173. DOI: 10.1177/1357633X18804749.
[25] [25] WILLIAMS G A, SCOTT I U, HALLER J A, et al. Single-field fundus photography for diabetic retinopathy screening: a report by the American Academy of Ophthalmology[J]. Ophthalmology, 2004, 111(5): 1055-1062. DOI: 10.1016/j.ophtha.2004.02.004.
[31] [31] TING D S W, CHEUNG C Y, LIM G, et al. Development and validation of a deep learning system for diabetic retinopathy and related eye diseases using retinal images from multiethnic populations with diabetes[J]. JAMA, 2017, 318(22): 2211-2223. DOI: 10.1001/jama.2017.18152.
[32] [32] GARGEYA R, LENG T. Automated identification of diabetic retinopathy using deep learning[J]. Ophthalmology, 2017, 124(7): 962-969. DOI: 10.1016/j.ophtha.2017.02.008.
[33] [33] PARK C W, SEO S W, KANG N, et al. Artificial intelligence in health care: current applications and issues[J]. J Korean Med Sci, 2020, 35(42): e379. DOI: 10.3346/jkms.2020.35.e379.
[34] [34] U.S. Food and Drug Administration. FDA permits marketing of artificial intelligence-based device to detect certain diabetes-related eye problems[EB/OL]. (2018-08-12) [2025-04-25]. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm604357.htm.
Get Citation
Copy Citation Text
LEI Boya, WANG Xin, CHU Ruilin, WEN Wen, WEI Wenbin, XU Gezhi, CHANG Qing, ZHANG Ting. Research status on medical quality control for diabetic retinopathy screening and clinical classification[J]. Chinese Journal of Ophthalmology and Otorhinolaryngology, 2025, 25(4): 292
Special Issue:
Received: Apr. 28, 2025
Accepted: Aug. 25, 2025
Published Online: Aug. 25, 2025
The Author Email: ZHANG Ting (tina-chang07@163.com)
